A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a swedish biopsy cohort

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 2, 2014, Pages 136-141

  Svensson, Maria A ^a   Perner, Sven ^b   Ohlson, Anna Lena ^a   Day, John R ^c   Groskopf, Jack ^c   Kirsten, Robert ^b   Sollie, Thomas ^a   Helenius, Gisela ^a   Andersson, Swen Olof ^a   Demichelis, Francesca ^d,e   Andrén, Ove ^a   Rubin, Mark A ^e  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Gen Probe Incorporated   (United States)

^d UNIVERSITY OF TRENTO   (Italy)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ERG; gene fusion; prostate cancer

Indexed keywords

DNA; MESSENGER RNA; TRANSCRIPTION FACTOR ERG;

AGED; ARTICLE; COHORT ANALYSIS; FISHER EXACT TEST; GENE FUSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SWEDEN;

AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CARCINOMA; COHORT STUDIES; DNA; FEASIBILITY STUDIES; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SWEDEN; TRANS-ACTIVATORS;

EID: 84896712983     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31829e0484     Document Type: Article

References (30)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
3. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11:804-811.
4. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-4711.
5. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-1067.
6. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275-286.
7. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089-1095.
8. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.
9. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12:590-598.
10. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011;459:441-447.
11. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24:1128-1138.
12. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
13. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347-8351.
14. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888.
15. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337-8341.
16. Esgueva R, Perner S, J LaFargue C, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010;23:539-546.
17. Svensson MA, LaFargue CJ, MacDonald TY, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest. 2011; 91:404-412.
18. Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012;15: 165-169.
19. Braun M, Scheble VJ, Menon R, et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology. 2011;58:1028-1036.
20. Perner S, Svensson MA, Hossain RR, et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology. 2010;75:762-767.
21. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006;8:465-469.
22. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 2007;20:921-928.
23. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26: 2667-2673.
24. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006;45:717-719.
25. Wang J, Cai Y, Yu W, et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008;68:8516-8524.
26. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neo-plasia and potential clinical implications. Clin Cancer Res. 2008; 14:3380-3385.
27. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645-649.
28. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13:5103-5108.
29. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006;8:885-888.
30. Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS. 2009;117: 575-582.